STIM Stock Overview
A commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Neuronetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.89 |
| 52 Week High | US$5.07 |
| 52 Week Low | US$0.52 |
| Beta | 2.22 |
| 11 Month Change | -10.61% |
| 3 Month Change | -6.55% |
| 1 Year Change | -38.97% |
| 33 Year Change | -78.52% |
| 5 Year Change | -79.51% |
| Change since IPO | -96.81% |
Recent News & Updates
Neuronetics, Inc. (NASDAQ:STIM) Analysts Just Slashed Next Year's Revenue Estimates By 12%
Nov 18
A Piece Of The Puzzle Missing From Neuronetics, Inc.'s (NASDAQ:STIM) 28% Share Price Climb
Nov 05Recent updates
Neuronetics, Inc. (NASDAQ:STIM) Analysts Just Slashed Next Year's Revenue Estimates By 12%
Nov 18A Piece Of The Puzzle Missing From Neuronetics, Inc.'s (NASDAQ:STIM) 28% Share Price Climb
Nov 05Investors Give Neuronetics, Inc. (NASDAQ:STIM) Shares A 60% Hiding
Aug 13Here's Why Shareholders May Want To Be Cautious With Increasing Neuronetics, Inc.'s (NASDAQ:STIM) CEO Pay Packet
May 24The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 09Neuronetics: Reality Set In
May 09Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 36% Lower
May 08Neuronetics (NASDAQ:STIM) Has Debt But No Earnings; Should You Worry?
May 01Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely
Mar 17Neuronetics: Modest Improvements Are Not Enough
Jan 30Neuronetics, Inc. (NASDAQ:STIM) Soars 61% But It's A Story Of Risk Vs Reward
Dec 19Neuronetics, Inc.'s (NASDAQ:STIM) Shares Not Telling The Full Story
Jun 21Does Neuronetics (NASDAQ:STIM) Have A Healthy Balance Sheet?
May 10Neuronetics: Growth To Capture, But Fairly Priced
Sep 06Is Neuronetics (NASDAQ:STIM) Using Debt Sensibly?
Sep 06Neuronetics gets FDA nod for its D-Tect accessory product for use to treat depression
Aug 29Neuronetics GAAP EPS of -$0.39 beats by $0.02, revenue of $16.3M beats by $0.84M , revises FY guidance
Aug 02Neuronetics stock soars 30% as FDA clears NeuroStar system for anxious depression
Jul 19Is Neuronetics (NASDAQ:STIM) A Risky Investment?
Jun 08Shareholder Returns
| STIM | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 24.6% | 1.5% | 2.2% |
| 1Y | -39.0% | 20.8% | 31.6% |
Return vs Industry: STIM underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: STIM underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| STIM volatility | |
|---|---|
| STIM Average Weekly Movement | 18.2% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: STIM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: STIM's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 201 | Keith Sullivan | neurostar.com |
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
Neuronetics, Inc. Fundamentals Summary
| STIM fundamental statistics | |
|---|---|
| Market cap | US$26.86m |
| Earnings (TTM) | -US$36.42m |
| Revenue (TTM) | US$72.71m |
0.4x
P/S Ratio-0.7x
P/E RatioIs STIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STIM income statement (TTM) | |
|---|---|
| Revenue | US$72.71m |
| Cost of Revenue | US$15.77m |
| Gross Profit | US$56.94m |
| Other Expenses | US$93.36m |
| Earnings | -US$36.42m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | 78.31% |
| Net Profit Margin | -50.09% |
| Debt/Equity Ratio | 490.4% |
How did STIM perform over the long term?
See historical performance and comparison